Learn more ZELPULTIDE ALFA A First-in-Class Biologic Designed to Modulate Inflammation and Facilitate Infection Clearance

OUR VISION

We envision a future where our immune-modulating therapies fundamentally change how we prevent and treat respiratory, inflammatory, and infectious diseases. Through our first-in-class biologic, zelpultide alfa, we aim to break the destructive cycle of dysregulated inflammation and infection by modulating immune responses at the source. Guided by science, we are building a platform that helps patients breathe easier, recover faster, and live longer, healthier lives, driving a global shift in the understanding and treatment of immune-driven conditions.

OUR IMPACT

Zelpultide alfa is a first-in-class recombinant protein that replicates the structure and function of native surfactant protein D (SP-D). Engineered to restore the body’s natural ability to modulate and reduce inflammation, and enhance infection clearance, it provides a preventive and therapeutic solution for a broad range of acute and chronic inflammatory and infectious diseases across all ages — from extremely preterm neonates to adults.

PRESS RELEASES

Airway Therapeutics Awarded $1.9 Million NIH Grant to Advance Phase 2b/3 Study of Zelpultide Alfa for Prevention of Bronchopulmonary Dysplasia

September 29, 2026

Airway Therapeutics Closes $50 Million Equity Round to Advance Late-Stage Development of Zelpultide Alfa

August 25, 2026

Airway Therapeutics Appoints Biopharma Leader Joe Todisco to Board of Directors

April 13, 2026